Amicus Therapeutics Gets European Commission Approval For Galafold in Patients With Fabry Disease

By: via Benzinga
Amicus Therapeutics (Nasdaq: FOLD) revealed that the European Commission has granted full approval for its oral small molecule ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.